Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Pain, Prostatic Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

CELLO-1

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

LUNAAR

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

DUALIDES

Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer